Vol. 4 No. 7 (2024): July
Reimbursement Reviews

Nirmatrelvir-Ritonavir (Paxlovid)

decorative image of the issue cover

Published July 9, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nirmatrelvir-ritonavir (Paxlovid), 150 mg nirmatrelvir; 100 mg ritonavir, tablets, co-packaged for oral use.
  • Indication: For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.